Cancer Stem Cells Under Hypoxia as a Chemoresistance Factor in the Breast and Brain

Current Pathobiology Reports

Volumn 2, Issue 1, 2014, Pages 33-40

  Crowder, Spencer W ^a,b   Balikov, Daniel A ^a,b   Hwang, Yu Shik ^c   Sung, Hak Joon ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Kyung Hee University   (South Korea)

Author keywords

Brain cancer; Breast cancer; Cancer stem cells; Chemoresistance; Hypoxia; Metastasis

Indexed keywords

EID: 84911411198     PISSN: None     EISSN: 2167485X     Source Type: Journal    
DOI: 10.1007/s40139-013-0035-6     Document Type: Article

References (62)

1. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355(12):1253–1261. doi:10.1056/NEJMra061808
2. Schwarz G (1906) Ueber Desensibilisierung gegen Roentgen-und Radium-strahlen. Muenchner Medizinische Wochenschrift 56:1217–1218
3. Churchill-Davidson I, Sanger C, Thomlinson RH (1955) High-pressure oxygen and radiotherapy. Lancet 268(6874):1091–1095
4. Shrieve DC, Harris JW (1985) The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers. Int J Radiat Biol Relat Stud Phys Chem Med 48(1):127–138
5. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C et al (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24(7):2875–2889
6. Zolzer F, Streffer C (2002) Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 54(3):910–920
7. 2 availability on human cancer. Nat Rev Cancer 8(12):967–975. doi:10.1038/nrc2540
8. Young SD, Marshall RS, Hill RP (1988) Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA 85(24):9533–9537
9. Zhang L, Hill RP (2004) Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res 64(12):4180–4189. doi:10.1158/0008-5472.CAN-03-3038
10. Zhang L, Hill RP (2007) Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion. Cancer Res 67(16):7789–7797. doi:10.1158/0008-5472.CAN-06-4221
11. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192. doi:10.1038/nrc2344
12. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E et al (2003) The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22(21):3213–3220. doi:10.1038/sj.onc.1206385
13. Hammer S, To KK, Yoo YG, Koshiji M, Huang LE (2007) Hypoxic suppression of the cell cycle gene CDC25A in tumor cells. Cell Cycle 6(15):1919–1926
14. Li CY, Little JB, Hu K, Zhang W, Zhang L, Dewhirst MW et al (2001) Persistent genetic instability in cancer cells induced by non-DNA-damaging stress exposures. Cancer Res 61(2):428–432
15. Reynolds TY, Rockwell S, Glazer PM (1996) Genetic instability induced by the tumor microenvironment. Cancer Res 56(24):5754–5757
16. Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M (1998) A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 2(2):259–265
17. Wang M, Kirk JS, Venkataraman S, Domann FE, Zhang HJ, Schafer FQ et al (2005) Manganese superoxide dismutase suppresses hypoxic induction of hypoxia-inducible factor-1 alpha and vascular endothelial growth factor. Oncogene 24(55):8154–8166. doi:10.1038/sj.onc.1208986
18. Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6):425–437. doi:10.1038/nrc2397
19. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q et al (2007) Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26(1):63–74. doi:10.1016/j.molcel.2007.02.024
20. Quintero M, Brennan PA, Thomas GJ, Moncada S (2006) Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res 66(2):770–774. doi:10.1158/0008-5472.CAN-05-0333
21. Moeller BJ, Cao Y, Li CY, Dewhirst MW (2004) Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5(5):429–441
22. Nayak BK, Feliers D, Sudarshan S, Friedrichs WE, Day RT, New DD et al (2013) Stabilization of HIF-2alpha through redox regulation of mTORC2 activation and initiation of mRNA translation. Oncogene 32(26):3147–3155. doi:10.1038/onc.2012.333
23. Kim JW, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177–185. doi:10.1016/j.cmet.2006.02.002
24. Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8(9):705–713. doi:10.1038/nrc2468
25. Brahimi-Horn MC, Chiche J, Pouyssegur J (2007) Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 19(2):223–229. doi:10.1016/j.ceb.2007.02.003
26. Mathupala SP, Rempel A, Pedersen PL (2001) Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 276(46):43407–43412. doi:10.1074/jbc.M108181200
27. Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F et al (2003) Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 162(4):1283–1291
28. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19(48):5435–5443. doi:10.1038/sj.onc.1203938
29. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379(6560):88–91. doi:10.1038/379088a0
30. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC (2007) HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11(4):335–347. doi:10.1016/j.ccr.2007.02.006
31. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE et al (2008) HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6):435–446. doi:10.1016/j.ccr.2008.10.016
32. Liu MY, Poellinger L, Walker CL (2003) Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene. Cancer Res 63(10):2675–2680
33. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988. doi:10.1073/pnas.0530291100
34. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186. doi:10.1056/NEJM197111182852108
35. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239. doi:10.1016/j.ccr.2009.01.021
36. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231. doi:10.1016/j.ccr.2009.01.027
37. Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Korkaya H, Heath AN et al (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 109(8):2784–2789. doi:10.1073/pnas.1018866109
38. Lagadec C, Dekmezian C, Bauche L, Pajonk F (2012) Oxygen levels do not determine radiation survival of breast cancer stem cells. PLoS One 7(3):e34545. doi:10.1371/journal.pone.0034545
39. Swietach P, Hulikova A, Vaughan-Jones RD, Harris AL (2010) New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 29(50):6509–6521. doi:10.1038/onc.2010.455
40. Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Chafe SC, Ostlund C et al (2013) Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. doi:10.1038/onc.2012.550
41. • Harrison H, Rogerson L, Gregson HJ, Brennan KR, Clarke RB, Landberg G (2013) Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-alpha status. Cancer Res 73(4):1420–1433. doi: 10.1158/0008-5472.CAN-12-2505. Using immortalized cell lines and patient tissue samples, this paper demonstrated contrasting effects of hypoxia on CSC enrichment, based upon estrogen receptor-alpha status of the overall tumor
42. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR et al (2010) Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 70(2):709–718. doi:10.1158/0008-5472.CAN-09-1681
43. •• Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W et al (2011) Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 30(39):4075–4086. doi:10.1038/onc.2011.122. Investigation of Notch ligand expression from >700 patients in GEO database and >60 clinical samples showed that Jagged2 and Notch expression correlate negatively with positive clinical outcome and metastasis-free survival. This study provides a potential prognostic indicator for breast cancer diagnostics
44. Peng ST, Su CH, Kuo CC, Shaw CF, Wang HS (2007) CD44 crosslinking-mediated matrix metalloproteinase-9 relocation in breast tumor cells leads to enhanced metastasis. Int J Oncol 31(5):1119–1126
45. Krishnamachary B, Penet MF, Nimmagadda S, Mironchik Y, Raman V, Solaiyappan M et al (2012) Hypoxia regulates CD44 and its variant isoforms through HIF-1alpha in triple negative breast cancer. PLoS One 7(8):e44078. doi:10.1371/journal.pone.0044078
46. Hwang-Verslues WW, Chang PH, Wei PC, Yang CY, Huang CK, Kuo WH et al (2011) miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene 30(21):2463–2474. doi:10.1038/onc.2010.618
47. Kim RJ, Park JR, Roh KJ, Choi AR, Kim SR, Kim PH et al (2013) High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett 333(1):18–31. doi:10.1016/j.canlet.2012.11.026
48. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S et al (2004) Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 64(19):7011–7021. doi:10.1158/0008-5472.CAN-04-1364
49. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396–401. doi:10.1038/nature03128
50. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF (2013) Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 19(16):4392–4403. doi:10.1158/1078-0432.CCR-12-1557
51. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV et al (2012) Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neurooncology 14(11):1379–1392. doi:10.1093/neuonc/nos158
52. Li P, Zhou C, Xu L, Xiao H (2013) Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study. Int J Med Sci 10(4):399–407. doi:10.7150/ijms.5407
53. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N et al (2011) Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103(1):43–58. doi:10.1007/s11060-010-0357-8
54. •• Mathieu J, Zhang Z, Zhou W, Wang AJ, Heddleston JM, Pinna CM et al (2011) HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 71(13):4640–4652. doi:10.1158/0008-5472.CAN-10-3320. Compared various cancer lines lines to human embryonic stem cells grown under hypoxia to located overlapping gene expression profiles. This study discovered that there were trends in stemness markers and hypoxia inducible factors
55. Bar EE, Lin A, Mahairaki V, Matsui W, Eberhart CG (2010) Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. Am J Pathol 177(3):1491–1502. doi:10.2353/ajpath.2010.091021
56. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, Meletis K et al (2010) A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 133(Pt 4):983–995. doi:10.1093/brain/awq042
57. Mendez O, Zavadil J, Esencay M, Lukyanov Y, Santovasi D, Wang SC et al (2010) Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer 9:133. doi:10.1186/1476-4598-9-133
58. • Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE et al (2012) Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell death and differentiation 19(3):428–439. doi:10.1038/cdd.2011.109. Determined that MLL1 was a downstream target of hypoxia inducible factor that altered methylation profiles of glioblastoma stem cells. This paper was one of the first to show epigenetic changes as a consequence of hypoxia inducible factor expression from low oxygen settings
59. Mao XG, Xue XY, Wang L, Zhang X, Yan M, Tu YY et al (2013) CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia. Neurooncology 15(7):865–879. doi:10.1093/neuonc/not029
60. Crowder SW, Horton LW, Lee SH, McClain CM, Hawkins OE, Palmer AM et al (2013) Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. Faseb J 27(7):2788–2798. doi:10.1096/fj.13-228288
61. Szot CS, Buchanan CF, Freeman JW, Rylander MN (2011) 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials 32(31):7905–7912. doi:10.1016/j.biomaterials.2011.07.001
62. Moore M, Moore R, McFetridge PS (2013) Directed oxygen gradients initiate a robust early remodeling response in engineered vascular grafts. Tissue Eng Part A 19(17–18):2005–2013. doi:10.1089/ten.TEA.2012.0592